ARJUN GOYAL - 15 May 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Director
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Issuer symbol
CNTA
Transactions as of
15 May 2025
Net transactions value
+$5,865,242
Form type
4
Filing time
19 May 2025, 17:49:01 UTC
Previous filing
27 Jun 2024
Next filing
24 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOYAL ARJUN Director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Gregory Weinhoff, attorney-in-fact 19 May 2025 0001861844

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Purchase $550,238 +44,939 $12.24 44,939 15 May 2025 See footnote F1, F2, F3
transaction CNTA Ordinary Shares Purchase $5,315,005 +417,646 +929% $12.73 462,585 16 May 2025 See footnote F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.99 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3 Shares held by Vinyanshu Ventures LLC, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership of the shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.45 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.